|
Age, median (25%, 75%)
|
41 (35–49)
|
41 (34–49)
|
40 (35–48)
|
|
Male sex, n (%)
|
77 (83)
|
49 (80)
|
23 (88)
|
|
Drug use in the last 6 months (injecting/non-injecting)
|
77 (83)
|
48 (79)
|
25 (96)
|
|
Injecting drug use in the last month
|
55 (59)
|
39 (64)
|
15 (58)
|
|
Heroin
|
33 (35)
|
23 (37)
|
10 (38)
|
|
Cocaine
|
10 (11)
|
7 (11)
|
3 (12)
|
|
Amphetamines
|
14 (15)
|
7 (11)
|
6 (23)
|
|
Other opiates
|
11 (12)
|
8 (13)
|
3 (12)
|
|
Benzodiazapines
|
2 (2)
|
2 (3)
|
0 (0)
|
|
Injecting drug use frequency in the last month
|
|
Never
|
38 (41)
|
22 (36)
|
11 (42)
|
|
< daily
|
40 (43)
|
29 (48)
|
10 (38)
|
|
> daily
|
15 (16)
|
10 (16)
|
5 (19)
|
|
Opioid substitution treatment (ever)
|
82 (88)
|
56 (92)
|
21 (81)
|
|
OST and recent injecting (past month) at enrolment
|
|
No OST, recent injecting
|
30 (32)
|
20 (33)
|
9 (33)
|
|
OST, no recent injecting
|
23 (25)
|
15 (25)
|
5 (19)
|
|
OST, recent injecting
|
40 (43)
|
26 (43)
|
12 (44)
|
|
OST and recent injecting (past month) at baseline
|
|
No OST, recent injecting
|
21 (23)
|
14 (23)
|
6 (23)
|
|
OST, no recent injecting
|
34 (37)
|
21 (34)
|
8 (31)
|
|
OST, recent injecting
|
38 (41)
|
26 (43)
|
12 (46)
|
|
Stage of liver disease
|
|
No or mild fibrosis (F0-F1)
|
63 (68)
|
44 (72)
|
16 (62)
|
|
Moderate or advanced fibrosis (F2-F3)
|
20 (22)
|
12 (20)
|
5 (19)
|
|
Cirrhosis (F4)
|
10 (11)
|
5 (8)
|
5 (19)
|
|
Study site distribution
|
|
Europe
|
38 (41)
|
24 (39)
|
13 (50)
|
|
Australia
|
40 (43)
|
27 (44)
|
9 (35)
|
|
Canada
|
15 (16)
|
10 (16)
|
4 (15)
|
